Kura Oncology (NASDAQ:KURA) Insider Sells $51,662.05 in Stock

Key Points

• Insider sale: Brian Powl sold 4,345 Kura Oncology shares for approximately $51,662 at an average price of $11.89, reducing his direct ownership by 2.5% to 169,269 shares.
• Recent performance: KURA shares rose to $12.40, near their 12-month high of $12.90. The company exceeded quarterly EPS and revenue expectations, although it remains unprofitable with a negative net margin.
• Analyst outlook: Analysts maintain a “Moderate Buy” consensus, with an average price target of $25.40—more than double the reported share price—while institutional investors have recently increased or initiated positions.

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) insider Brian Powl sold 4,345 shares of the business's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $11.89, for a total transaction of $51,662.05. Following the sale, the insider directly owned 169,269 shares of the company's stock, valued at approximately $2,012,608.41. This trade represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA traded up $0.51 during midday trading on Monday, reaching $12.40. 2,673,296 shares of the company traded hands, compared to its average volume of 1,620,411. Kura Oncology, Inc. has a 12 month low of $7.36 and a 12 month high of $12.90. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -3.68 and a beta of 0.38. The firm's fifty day moving average price is $10.53 and its two-hundred day moving average price is $9.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The business had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. On average, equities analysts expect that Kura Oncology, Inc. will post -3.23 earnings per share for the current year.

Institutional Trading of Kura Oncology

A number of institutional investors have recently modified their holdings of KURA. IFP Advisors Inc grew its holdings in Kura Oncology by 115.3% in the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company's stock valued at $25,000 after buying an additional 1,284 shares during the last quarter. Allworth Financial LP lifted its position in shares of Kura Oncology by 59.9% during the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company's stock worth $43,000 after buying an additional 1,553 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Kura Oncology by 49.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company's stock valued at $60,000 after buying an additional 1,888 shares in the last quarter. Insigneo Advisory Services LLC acquired a new stake in Kura Oncology in the 4th quarter valued at $105,000. Finally, LPL Financial LLC bought a new stake in Kura Oncology in the fourth quarter valued at $105,000.

Analyst Ratings Changes

Several research analysts recently issued reports on KURA shares. Raymond James Financial set a $24.00 target price on shares of Kura Oncology in a report on Monday. Wells Fargo & Company set a $24.00 target price on shares of Kura Oncology in a research note on Thursday, June 4th. Wall Street Zen upgraded shares of Kura Oncology from a "strong sell" rating to a "hold" rating in a report on Saturday, May 16th. Citizens Jmp reaffirmed a "market outperform" rating and set a $24.00 target price on shares of Kura Oncology in a research note on Monday. Finally, Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a report on Monday. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Kura Oncology currently has an average rating of "Moderate Buy" and an average price target of $25.40.

Kura Oncology Company Profile

Kura Oncology, Inc NASDAQ: KURA is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source